Accent Therapeutics is pioneering the development of small molecule therapeutics that target RNA-modifying proteins (RMPs) to address significant unmet medical needs in cancer treatment. Their innovative approach focuses on identifying and exploiting critical intracellular dependencies across various cancer types, rather than solely targeting mutation-specific vulnerabilities. This strategy has led to the discovery of several promising programs, including first-in-class and best-in-class candidates, aimed at benefiting large patient populations. The company’s pipeline includes therapies designed for high-impact oncogenic targets, with a commitment to advancing drug candidates through rigorous preclinical and IND-enabling studies.

The company’s lead programs include a first-in-class inhibitor of DHX9, which is implicated in several cancer types and has shown potential in treating tumors with BRCA loss of function and deficient mismatch repair. Additionally, Accent is developing inhibitors for KIF18A and ADAR1, both of which are critical targets in various solid tumors. Their research emphasizes the importance of biomarker-driven approaches to optimize patient outcomes, and they are actively exploring combinations of their therapies with existing cancer treatments to enhance efficacy. Through a robust pipeline and strategic partnerships, Accent Therapeutics aims to transform cancer care by delivering innovative therapies that leverage their deep understanding of cancer biology.

United States

Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to target identification and validation. Our seasoned team of drug developers is uniquely experienced to interrogate and advance small molecule therapies with far-reaching potential.

Accent Therapeutics

Company Details